Список литературы

1. Черноусов А.Ф., Поликарпов С.А., Годжело Э.А. Ранний рак и предопухолевые заболевания желудка - М.: ИздАТ, 2002. - 256 с.

2. Щепотин И.Б., Эванс С.Р. Рак желудка: практическое руководство по профилактике, диагностике и лечению. Киев "Книга Плюс" 2000. - 227 с.

3. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под редакцией М.И. Давыдова и Е.М. Аксель М., Издательская группа РОНЦ, 2014, 226 страниц

4. Adachi, Y. Persistence of mucosal gastric carcinomas for 8 and 6 years in two patients/Y. Adachi, M. Mori, K. Sugimachi//Arch. Pathol. Lab. Med. - 1990. - Vol. 114. - P. 1046 - 1048.

5. Adachi, Y. Prognostic significance of the number of positive lymph nodes in gastric carcinoma/Y. Adachi, T. Kamakura, M. Mori et al.//Br. J. Surg. - 1994. - Vol. 81. - P. 414 - 416.

6. Ito, H. Complete ten-year postgastrectomy follow-up of early gastric cancer./H. Ito, Y Oohata, K. Nakamura et al.//Am. J. Surg. - 1989. - Vol. 158. - P. 14 - 16.

7. Isozaki, H. Distant lymph node metastasis of early gastric cancer./H. Isozaki, K. Okajima, T. Ichinowa et al.//Jpn. J. Surg. - 1997. - Vol. 27. - P. 600 - 605.

8. Германов, А.Б. Расширенные и расширенно-комбинированные операции при раке проксимального отдела желудка. Диссертация доктора медицинских наук./А.Б. Германов//- М. - 1998. - 312 С.

9. Давыдов, М.И. Хирургическое лечение рака проксимального отдела желудка. Материалы V Ежегодной Российской Онкологической Конференции/М.И. Давыдов, М.Д. Тер-Ованесов, И.С. Стилиди//- М. - 2002. 165 - 167.

10. Давыдов, М.И. Идеология расширенных операций по поводу рака желудка./М.И. Давыдов, Б.Е. Полоцкий, И.С. Стилиди и др.//Вестник Московского Онкологического Общества. - Москва. - N 494. - 2003. - С. 2 - 3.

11. Рак желудка. В книге "Энциклопедия клинической онкологии" под редакцией М.И. Давыдова./Давыдов М.И., Тер-Ованесов М.Д., Полоцкий Б.Е. и др. - М: РЛС, 2004. - С. 223 - 230.

12. Давыдов, М.И. Энциклопедия хирургии рака желудка./М.И. Давыдов, И.Н. Туркин, М.М. Давыдов - Москва: ЭКСМО, 2011. - С. 536.

13. Поликарпов, С.А. Актуальные проблемы хирургии рака желудка. Диссертация доктора медицинских наук./С.А. Поликарпов - Москва, 2003. - С. 152.

14. Стилиди, И.С. Современные представления об основных принципах хирургического лечения местно-распространенного рака желудка./И.С. Стилиди, С.Н. Неред//Практическая онкология. - 2009. - Т. 10. - N 1. - С. 20 - 27.

15. Katai, H. Risk factors for pancreas-related abscess after total gastrectomy./H. Katai, K. Yoshimura, T. Fukagawa//Gastric Cancer. - 2005. - N 8 (3). - P. 137 - 141.

16. Yu, W. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer./W. Yu, G.S. Choi, H.Y Chung//Br. J. Surg. - 2006. - Vol. 93 (5). - P. 559 - 563.

17. Sasako M., Yamaguchi T., Kinoshita T. et al. Randomized phase III trial comparing S 1 monotherapy versus surgery alone for stage II/III gastric cancer patients (pts) after curative D2 gastrectomy (ACTS GC study)/ASCO 2007 Gastrointestinal Cancers Symposium. - 2007. - P. Abstr 8.

18. Cunningham D., Allum W.H., Stenning S.P. et al. Perioperative chemotherapy versus surgery alone for resectable gastroe sophageal cancer//N. Engl. J. Med. - 2006. - Vol. 355. - P. 11 20.

19. Ychou M., Pignon J.P., Lasser P. et al. Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (C) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNCLCC 94012 FFCD 9703 trial//Proc. Am. Soc. Clin. Oncol. - 2006. - Vol. 24 (18S): Abstract 4026.

20. MacDonald J.S., Smalley S., Benedetti J. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction//N. Engl. J. Med. - 2001. - Vol. 345. - P. 725.

21. Ichikawa H. X ray diagnosis of gastric cancer//Gastric Cancer/Nishi M., Ichikawa H. et al (eds.). - Springer Verlag, 1993. - P. 232 - 245.

22. Tsuda Y. Endoscopic observation of gastric lesions with a dye spraying technique//Endoscopic Gastroenterology - 1987. - Vol. 9. - P. 189 - 195.

23. Yoshida S., Yamaguchi H., Saito D., Kido M. Endoscopic diagnosis: latest trends//Gastric Cancer/Nishi M., Ichikawa H. etal. (eds.). - Springer Verlag, 1993. - P. 246 - 262.

24. Murata Y, Suzuki S., Oguma H. et al., Recent progress in staging gastric cancer by endoscopic ultrasonography//proceeding of 3rd International Gastric Cancer Congress, Seoul, Korea, 1999. - Monduzzi Editore, 1999. - Vol. 1. - P. 109 - 114.

25. Fukuya T., Honda H., Kaneko K. et al. Efficacy of helical CT in T staging of gastric cancer//J. Comput. Assist. Tomography. - 1997. - Vol. 21. - P. 73 - 81.

26. Takao M., Fukuda T., Iwanaga S. et al. Gastric cancer: evaluation of triphasic spiral CT and radiologic-pathologic correlation//J. Comput. Assist. Tomography. - 1998. - Vol. 22. - P. 288 - 294.

27. Staging Laparoscopy in the Management of Gastric Cancer: A Population-Based Analysis/Paul J Karanicolas, MD, PhD, Elena В Elkin, PhD, Lindsay M Jacks, MSc, Coral L Atoria, MPH, Vivian E Strong, MD, FACS, Murray F Brennan, MD, FACS, Daniel G Coit, MD, FACS//J Am Coll Surg 2011; 213: 644 - 651

28. Sawai K., Takahashi T., Suzuki H. New trends in surgery for gastric cancer//Jap. J. Surg. Oncol. - 1994. - Vol. 56. - P. 221 226.

29. Bozzetti, F. Subtotal Versus Total Gastrectomy for Gastric Cancer. Five-Year Survival Rates in a Multicenter Randomized Italian Trial./F. Bozzetti, E. Marubini, G. Bonfanti et al.//Ann. Surg. - 1999. - Vol. 230. - N 2. - P. 170 - 178.

30. Morgagni, P. for the Italian Research Group for Gastric Cancer Study. Does resection line involvement affect prognosis in early gastric cancer patients? An Italian Multicentric Study./P. Morgagni, D. Garcea, D. Marreli et al.//World J. Surg. - 2006. - Vol. 30. - P. 585 - 589.

31. Sano, T. Recurrence of early gastric cancer./T. Sano, M. Sasako, T. Kinoshita et al.//Cancer. - 1993. - Vol. 72. - P. 3174 - 3178.

32. Sano, T. No advantage of reoperation for positive resection margin in node positive gastric cancer patients./T. Sano, S. Mudan//Jpn. J. Clin. Oncol. - 1999. - Vol. 29. - P. 283 - 284.

33. Songun, I. Prognostic value of resection line involvement in patients undergoing curative resection for gastric cancer./I. Songun, J.J. Bonencamp, J. Hermans et al.//Eur. J. Cancer. - 1996. - Vol. 32A. - P. 433 - 437.

34. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-FU, doxorubicin and methotrexate in advanced gastric cancer. Cancer. 1993; 72: 37 - 41.

35. Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEM-TX) plus supportive care with best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995; 71: 587-91.

36. Scheithauer W., Kornek G., Heina M. et al. Palliative chemotherapy versus best supportive care in patients with metastatic gastric cancer: a randomized trial//Ann. Hematol. 1994. Vol. 73. Suppl. 2. Abstract A181.

37. Wagner A.D., Grothe W., Haerting J. et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data//J. Clin. Oncol. 2006. Vol. 24. No 18. P. 2903 - 2909.

38. Van Cutsem E, Chung H, Shen L .EfficacyresultsfromtheToGAtrial: AphaseIIIstduyoftrastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) In ASCO Annual Meeting, Orlando, FL, USA. J Clin Oncol 2009; LBA4509.

39. Di Lauro L, Fattoruso SI, Giacinti L, et al. Second-line chemotherapy with FOLFIRI in patients with metastatic gastric cancer (MGC) not previously treated with fluoropyrimidines [abstract]. J Clin Oncol 2009; 27 (Suppl 15): Abstract 454

40. Al-Batran (http://ascopubs.org/author/Al-Batran%2C+Salah-Eddin) SE, Homann (http://ascopubs.org/author/Homann%2C+Nils) N, Schmalenberg (http://ascopubs.org/author/Schmalenberg%2C+Harald) H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. DOI: 10.1200/JCO.2017.35.15_suppl.4004/oifriia/of Clinical Oncology 35, no. 15_suppl (May 20 2017) 4004 - 4004.

41. Cats A (https://www.ncbi.nlm.nih.gov/pubmed/?term=Cats%20A%5BAuthor%5D&cauthor=true&cauthor_uid=2965036 Jansen EPM (https://www.ncbi.nlm.nih.gov/pubmed/?term=Jansen%20EPM%5BAuthor%5D&cauthor=true&cauthor_uid=29 <...> van Grieken NCT (https://www.ncbi.nlm.nih.gov/pubmed/?term=van%20Grieken%20NCT%5BAuthor%5D&cauthor=true&cautho et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol, (https://www.ncbi.nlm.nih.gov/pubmed/?term=CRITICS+trial+gastric+lancet) 2018 Apr 9. pii: S1470-2045(18)30132-3. doi: 10.1016/S1470-2045(18)30132-3. [Epub ahead of print]

42. E. Van Cutsem, C Boni, J. Tabernero, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. (https://www.ncbi.nlm.nih.gov/pubmed/25416687) 2015 Jan; 26(l): 149-56.

43. Shah MA (https://www.ncbi.nlm.nih.gov/pubmed/?term=Shah%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=26438 Jaiijigian YY (https://www.ncbi.nlm.nih.gov/pubmed/?term=Janjigian%20YY%5BAuthor%5D&cauthor=true&cauthor_uid=2(Stoller R (https://www.ncbi.nlm.nih.gov/pubmed/?term=Stoller%20R%5BAuthor%5D&cauthor=true&cauthor_uid=26438 et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol. (https://www.ncbi.nlm.nih.gov/pubmed/26438119) 2015 Nov 20; 33(33): 3874-9.

44. Ajani JA (https://www.ncbi.nlm.nih.gov/pubmed/?term=Ajani%20 JA%5B Author%5D &cauthor=true&cauthor_uid=17664 Moiseyenko VM (https://www.ncbi.nlm.nih.gov/pubmed/?term=Moiseyenko%20VM%5BAuthor%5D&cauthor=true&cauthor_uid Tjulandin S (https://www.ncbi.nlm.nih.gov/pubmed/? term=Tjulandin%20S%5BAuthor%5D&cauthor=true&cauthor_uid=17 <...> (et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase HI trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. (https://www.ncbi.nlm.nih.gov/pubmed/17664467) 2007 Aug 1; 25(22): 3205-9.

45. Kang JH (https://www.ncbi.nlm.nih.gov/pubmed/? term=Kang%20JH%5BAuthor%5D&cauthor=true&cauthor_uid=22412 <...> Lee SI (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20SI%5BAuthor%5D&cauthor=true&cauthor_uid=2241214 <...> Lim DH (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lim%20DH%5BAuthor%5D&cauthor=true&cauthor_uid=224121 <...> et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase HI trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. (https://www.ncbi.nlm.nih.gov/pubmed/22412140) 2012 May 1; 30(13): 1513-8.

46. Hironaka S (https://www.ncbi.nlm.nih.gov/pubmed/?term=Hironaka%20S%5BAuthor%5D&cauthor=true&cauthor_uid=241 <...> Ueda S (https://www.ncbi.nlm.nih.gov/pubmed/?term=Ueda%20S%5BAuthor%5D&cauthor=true&cauthor_uid=241901 <...> Yasui H (https://www.ncbi.nlm.nih.gov/pubmed/?term=Yasui%20H%5BAuthor%5D&cauthor=true&cauthor_uid=241901 <...> et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. (https://www.ncbi.nlm.nih.gov/pubmed/24190112) 2013 Dec 10; 31(35): 4438-44.

47. Wilke H (https://www.ncbi.nlm.nih.gov/pubmed/?term=Wilke%20H%5BAuthor%5D&cauthor=true&cauthor_uid=252401 <...> Muro K (https://www.ncbi.nlm.nih.gov/pubmed/?term=Muro%20K%5BAuthor%5D&cauthor=true&cauthor_uid=252408 <...> Van Cutsem E (https://www.ncbi.nlm.nih.gov/pubmed/?term=Van%20Cutsem%20E%5BAuthor%5D&cauthor=true&cauthor_u <...> et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. (https://www.ncbi.nlm.nih.gov/pubmed/25240821) 2014 Oct; 15(11): 1224-35.

48. Fuchs CS (https://www.ncbi.nlm.nih.gov/pubmed/?term=Fuchs%20CS%5BAuthor%5D&cauthor=true&cauthor_uid=24094 <...> Tomasek J (https://www.ncbi.nlm.nih.gov/pubmed/?term=Tomasek%20J%5BAuthor%5D&cauthor=true&cauthor_uid=2409 <...> Yong C J (https://www.ncbi.nlm.nih.gov/pubmed/?term=Yong%20CJ%5BAuthor%5D&cauthor=true&cauthor_uid=240947 <...> et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. (https://www.ncbi.nlm.nih.gov/pubmed/24094768) 2014 Jan 4; 383(9911): 31 - 39.

49. Kang, Y.-K., Boku, N., Satoh, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 2017, 390(10111): 2461 - 2471.

Критерии оценки качества медицинской помощи Приложение А1. Состав рабочей группы